Sophie Beliard
Overview
Explore the profile of Sophie Beliard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
459
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lamothe S, Belalem I, Vantyghem M, Nobecourt E, Mosbah H, Beliard S, et al.
Diabetes Obes Metab
. 2025 Jan;
27(4):1815-1825.
PMID: 39829337
Aim: To describe the effects of Glucagon-like peptide-1 receptor agonists (GLP-1RA) in patients with familial partial lipodystrophy (FPLD) assessed in a real-life setting in a national reference network. Patients And...
2.
Azar Y, Ludwig T, Le Bon H, Strom T, Bluteau O, Di-Filippo M, et al.
Atherosclerosis
. 2024 Nov;
399:118596.
PMID: 39500114
Background And Aims: PCSK9 is a key regulator of LDL-cholesterol levels. PCSK9 gain of function variants (GOFVs) cause autosomal dominant hypercholesterolemia (ADH). The first described PCSK9-GOFV, p.Ser127Arg, almost exclusively reported...
3.
Beliard S, Saheb S, Litzler-Renault S, Vimont A, Valero R, Bruckert E, et al.
Arterioscler Thromb Vasc Biol
. 2024 May;
44(6):1447-1454.
PMID: 38695169
Background: Patients with homozygous familial hypercholesterolemia (HoFH) remain at very high cardiovascular risk despite the best standard of care lipid-lowering treatment. The addition of evinacumab, an angiopoietin-like protein 3 monoclonal...
4.
Peretti N, Vimont A, Mas E, Lemale J, Reynaud R, Tounian P, et al.
Arch Pediatr
. 2024 Mar;
31(3):188-194.
PMID: 38538465
Background: Heterozygous familial hypercholesterolemia (HeFH) predisposes to premature cardiovascular diseases. Since 2015, the European Atherosclerosis Society has advocated initiation of statins at 8-10 years of age and a low-density lipoprotein...
5.
Chaptal M, Maraninchi M, Musto G, Mancini J, Chtioui H, Dupont-Roussel J, et al.
Cells
. 2024 Mar;
13(6.
PMID: 38534331
High blood levels of low-density lipoprotein (LDL)-cholesterol (LDL-C) are associated with atherosclerosis, mainly by promoting foam cell accumulation in vessels. As cholesterol is an essential component of cell plasma membranes...
6.
Beliard S, Mourre F, Valero R
Diabetologia
. 2024 Feb;
67(6):974-984.
PMID: 38376536
Dyslipidaemias are major cardiovascular risk factors, especially in people with diabetes. In this area, next-generation therapies targeting circulating lipoparticle metabolism (LDL, VLDL, chylomicrons, HDL) have recently been approved by the...
7.
Paquette M, Cariou B, Bernard S, Hegele R, Gallo A, Genest J, et al.
Arterioscler Thromb Vasc Biol
. 2023 Nov;
44(2):505-512.
PMID: 38031840
Background: Familial hypercholesterolemia (FH) is a genetic condition causing premature atherosclerotic cardiovascular disease (ASCVD). It is well established that patients with FH should be treated with statin therapy. However, there...
8.
Vimont A, Beliard S, Valero R, Leleu H, Durand-Zaleski I
Diabetol Metab Syndr
. 2023 Jun;
15(1):128.
PMID: 37322499
Objective: Prognostic models in patients living with diabetes allow physicians to estimate individual risk based on medical records and biological results. Clinical risk factors are not always all available to...
9.
Paquette M, Bernard S, Cariou B, Hegele R, Genest J, Trinder M, et al.
J Clin Lipidol
. 2023 Apr;
17(3):376-383.
PMID: 37003850
Background: The association between familial hypercholesterolemia (FH) and premature atherosclerotic cardiovascular disease (ASCVD) is well established. Several risk factors other than the cumulative low-density lipoprotein cholesterol (LDL-C) have been shown...
10.
Ferrieres J, Farnier M, Bruckert E, Vimont A, Durlach V, Ferrari E, et al.
Atheroscler Plus
. 2023 Jan;
50:17-24.
PMID: 36643794
Background And Aims: Heterozygous familial hypercholesterolemia (HeFH) is increasingly better diagnosed and treatments can improve the cardiovascular prognosis. We evaluated the long-term cardiovascular risk of HeFH using the French REgistry...